CytomX Therapeutics (NASDAQ:CTMX) Upgraded to “Neutral” by JPMorgan Chase & Co.

CytomX Therapeutics (NASDAQ:CTMX) was upgraded by equities researchers at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research report issued to clients and investors on Monday, MarketBeat.com reports.

CytomX Therapeutics Trading Up 0.6 %

Shares of CytomX Therapeutics stock opened at $1.68 on Monday. The company has a fifty day moving average price of $2.05 and a 200 day moving average price of $1.64. CytomX Therapeutics has a twelve month low of $1.04 and a twelve month high of $2.86. The stock has a market cap of $113.79 million, a price-to-earnings ratio of -83.96 and a beta of 1.01.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, March 11th. The biotechnology company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01). The business had revenue of $26.61 million for the quarter, compared to the consensus estimate of $23.36 million. Analysts forecast that CytomX Therapeutics will post -0.21 earnings per share for the current year.

Insider Buying and Selling at CytomX Therapeutics

In other CytomX Therapeutics news, CEO Sean A. Mccarthy sold 20,223 shares of the company’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $2.09, for a total value of $42,266.07. Following the completion of the transaction, the chief executive officer now directly owns 524,481 shares of the company’s stock, valued at approximately $1,096,165.29. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 35,024 shares of company stock valued at $73,200 in the last ninety days. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On CytomX Therapeutics

Institutional investors have recently modified their holdings of the stock. AlphaMark Advisors LLC raised its stake in shares of CytomX Therapeutics by 119.8% in the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 12,635 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of CytomX Therapeutics by 737.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 266,836 shares of the biotechnology company’s stock valued at $344,000 after purchasing an additional 234,970 shares in the last quarter. Finally, Congress Park Capital LLC raised its stake in shares of CytomX Therapeutics by 112.8% in the 4th quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company’s stock valued at $371,000 after purchasing an additional 126,850 shares in the last quarter. Institutional investors and hedge funds own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.